Novartis: Essential Hypertension trials

The registry lists 27 Essential Hypertension studies with Novartis as lead sponsor. 0 are open to participants now and 19 have results posted.

Phase 1 1Phase 2 4Phase 3 16Phase 4 5No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Efficacy and Safety of CVAA489 in Hypertensive PatientsCompletedNCT02062645Phase 4Results posted
• Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential HypertensionCompletedNCT01785472Phase 3Results posted
• Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to AmlodipineCompletedNCT01663233Phase 3Results posted
• Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential HypertensionCompletedNCT01615198Phase 3Results posted
• Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential HypertensionCompletedNCT01599104Phase 3Results posted
• A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential HypertensionCompletedNCT01256411Phase 2Results posted
• Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential HypertensionCompletedNCT01237223Phase 3Results posted
• Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential HypertensionCompletedNCT01193101Phase 2Results posted
• An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of AgeCompletedNCT01151410Phase 3Results posted
• Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of AgeCompletedNCT01150357Phase 3Results posted
• Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive PatientsCompletedNCT01042392Phase 4Results posted
• Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential HypertensionCompletedNCT01001572Phase 3Results posted
• Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate HypertensionCompletedNCT00765947Phase 4Results posted
• A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential HypertensionCompletedNCT00758524Phase 2Results posted
• Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II HypertensionCompletedNCT00705575Phase 3Results posted
• A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential HypertensionCompletedNCT00667719Phase 3Results posted
• Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.CompletedNCT00654875Phase 4Results posted
• Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential HypertensionCompletedNCT00437645Phase 3Results posted
• Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential HypertensionCompletedNCT00425373Phase 2/3Results posted
• A Real-world Study of the Safety of Hypertension Medication Therapy in Japanese Patients With Naïve HypertensionCompletedNCT06683768
• Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With HypertensionCompletedNCT06604897
• A National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by MonotherapyCompletedNCT01241487Phase 4
• Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential HypertensionCompletedNCT01237873Phase 3
• Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus AmlodipineCompletedNCT01113047Phase 3
• Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential HypertensionCompletedNCT00424541Phase 1
• Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.CompletedNCT00343551Phase 3
• A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and HypercholesterolemiaCompletedNCT00254475Phase 3